C. Lewanski

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +9

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Platinum-based Therapy, Disease Progression, Medicine +10

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

David J. Pinato, Sarah Howlett, Diego Ottaviani et al. · JAMA Oncology · 2019 · 564 citations · Full text

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh Senan, Anthony Brade, Lu-hua Wang et al. · Journal of Clinical Oncology · 2016 · 423 citations

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay et al. · The Lancet Oncology · 2012 · 176 citations · Full text